Cargando…

Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches

Hepatitis B virus infection (HBV) is one of the most common causes of hepatitis, and may lead to cirrhosis or hepatocellular carcinoma. According to the World Health Organization (WHO), approximately 296 million people worldwide are carriers of the hepatitis B virus. Various nucleos(t)ide analogs, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadiea, Rahila Zannat, Sultana, Shahnaj, Chaki, Bijan Mohon, Islam, Tasnim, Dash, Sharmy, Akter, Sharmin, Islam, Md Sayeedul, Kazi, Taheruzzaman, Nagata, Abir, Spagnuolo, Rocco, Mancina, Rosellina Margherita, Hossain, Md Golzar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836293/
https://www.ncbi.nlm.nih.gov/pubmed/35163539
http://dx.doi.org/10.3390/ijms23031617
_version_ 1784649641904570368
author Sadiea, Rahila Zannat
Sultana, Shahnaj
Chaki, Bijan Mohon
Islam, Tasnim
Dash, Sharmy
Akter, Sharmin
Islam, Md Sayeedul
Kazi, Taheruzzaman
Nagata, Abir
Spagnuolo, Rocco
Mancina, Rosellina Margherita
Hossain, Md Golzar
author_facet Sadiea, Rahila Zannat
Sultana, Shahnaj
Chaki, Bijan Mohon
Islam, Tasnim
Dash, Sharmy
Akter, Sharmin
Islam, Md Sayeedul
Kazi, Taheruzzaman
Nagata, Abir
Spagnuolo, Rocco
Mancina, Rosellina Margherita
Hossain, Md Golzar
author_sort Sadiea, Rahila Zannat
collection PubMed
description Hepatitis B virus infection (HBV) is one of the most common causes of hepatitis, and may lead to cirrhosis or hepatocellular carcinoma. According to the World Health Organization (WHO), approximately 296 million people worldwide are carriers of the hepatitis B virus. Various nucleos(t)ide analogs, which specifically suppress viral replication, are the main treatment agents for HBV infection. However, the development of drug-resistant HBV strains due to viral genomic mutations in genes encoding the polymerase protein is a major obstacle to HBV treatment. In addition, adverse effects can occur in patients treated with nucleos(t)ide analogs. Thus, alternative anti-HBV drugs of plant origin are being investigated as they exhibit excellent safety profiles and have few or no side effects. In this study, phytomedicines/phytochemicals exerting significant inhibitory effects on HBV by interfering with its replication were reviewed based on different compound groups. In addition, the chemical structures of these compounds were developed. This will facilitate their commercial synthesis and further investigation of the molecular mechanisms underlying their effects. The limitations of compounds previously screened for their anti-HBV effect, as well as future approaches to anti-HBV research, have also been discussed.
format Online
Article
Text
id pubmed-8836293
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88362932022-02-12 Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches Sadiea, Rahila Zannat Sultana, Shahnaj Chaki, Bijan Mohon Islam, Tasnim Dash, Sharmy Akter, Sharmin Islam, Md Sayeedul Kazi, Taheruzzaman Nagata, Abir Spagnuolo, Rocco Mancina, Rosellina Margherita Hossain, Md Golzar Int J Mol Sci Review Hepatitis B virus infection (HBV) is one of the most common causes of hepatitis, and may lead to cirrhosis or hepatocellular carcinoma. According to the World Health Organization (WHO), approximately 296 million people worldwide are carriers of the hepatitis B virus. Various nucleos(t)ide analogs, which specifically suppress viral replication, are the main treatment agents for HBV infection. However, the development of drug-resistant HBV strains due to viral genomic mutations in genes encoding the polymerase protein is a major obstacle to HBV treatment. In addition, adverse effects can occur in patients treated with nucleos(t)ide analogs. Thus, alternative anti-HBV drugs of plant origin are being investigated as they exhibit excellent safety profiles and have few or no side effects. In this study, phytomedicines/phytochemicals exerting significant inhibitory effects on HBV by interfering with its replication were reviewed based on different compound groups. In addition, the chemical structures of these compounds were developed. This will facilitate their commercial synthesis and further investigation of the molecular mechanisms underlying their effects. The limitations of compounds previously screened for their anti-HBV effect, as well as future approaches to anti-HBV research, have also been discussed. MDPI 2022-01-30 /pmc/articles/PMC8836293/ /pubmed/35163539 http://dx.doi.org/10.3390/ijms23031617 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sadiea, Rahila Zannat
Sultana, Shahnaj
Chaki, Bijan Mohon
Islam, Tasnim
Dash, Sharmy
Akter, Sharmin
Islam, Md Sayeedul
Kazi, Taheruzzaman
Nagata, Abir
Spagnuolo, Rocco
Mancina, Rosellina Margherita
Hossain, Md Golzar
Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches
title Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches
title_full Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches
title_fullStr Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches
title_full_unstemmed Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches
title_short Phytomedicines to Target Hepatitis B Virus DNA Replication: Current Limitations and Future Approaches
title_sort phytomedicines to target hepatitis b virus dna replication: current limitations and future approaches
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836293/
https://www.ncbi.nlm.nih.gov/pubmed/35163539
http://dx.doi.org/10.3390/ijms23031617
work_keys_str_mv AT sadiearahilazannat phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches
AT sultanashahnaj phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches
AT chakibijanmohon phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches
AT islamtasnim phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches
AT dashsharmy phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches
AT aktersharmin phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches
AT islammdsayeedul phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches
AT kazitaheruzzaman phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches
AT nagataabir phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches
AT spagnuolorocco phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches
AT mancinarosellinamargherita phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches
AT hossainmdgolzar phytomedicinestotargethepatitisbvirusdnareplicationcurrentlimitationsandfutureapproaches